U.S. Markets closed

Spiros Segalas Comments on Danaher

- By Holly LaFon

Danaher (NYSE:DHR), a new position added during the quarter, is a diversified conglomerate whose subsidiaries design, manufacture, and market products and offer services geared to worldwide professional, medical and dental, industrial, and commercial markets. In February, the company announced that it is buying GE Life Sciences' biopharmaceutical business, a leading provider of instruments, consumables, and software that support the research, discovery, process development, and manufacturing workflows of biopharmaceutical drugs. In our view, the business is attractive for its recurring revenue and distinct and scarce life sciences and diagnostics capabilities. We believe that Danaher is likely to establish a dominant position in the bioproduction/manufacturing industry.

From Spiros Segalas (Trades, Portfolio)' first-quarter 2019 Harbor Capital Appreciation Fund commentary.
This article first appeared on GuruFocus.